My watch list  

Potential New Treatment for Heart Attack

Prospective drug found by testing in human heart muscle grown from stem cells


Domainex announced that a team of its scientists, working in close partnership with Professor Michael Schneider and his team at Imperial College, have found a potential new drug candidate for treating the heart damage caused during a heart attack by targeting the way the heart reacts to stress, according to new research partially funded by the British Heart Foundation (BHF) and published in the journal, Cell Stem Cell.

The research team, led by BHF Professor Michael Schneider at the National Heart and Lung Institute, Imperial College London, was the first to discover that a protein called MAP4K4 plays a central role in how heart muscle cells die off as a response to the stress of a heart attack. It has gone on to develop a potential drug that targets this protein, and which in mouse studies can minimise the damage after a heart attack by 60 per cent.

A heart attack happens when a blood clot blocks one of the main coronary arteries, the blood vessels supplying the heart muscle. The heart is starved of oxygen and nutrients and the muscle produces stress signals that ultimately cause heart cells to die. These dead cells are not replaced very well, and this means that the damaged heart can’t pump effectively and this can lead to heart failure. Heart failure is a debilitating condition that makes everyday tasks like climbing stairs, or even getting dressed, exhausting.

Due in large part to research funded by the BHF more people than ever before are surviving their heart attack after receiving treatments such as stents and clot-busting drugs, but this means that the number of people living with heart failure has risen considerably. There are estimated to be over 900,000 people living with heart failure in the UK.

BHF Professor Michael Schneider and his team are working to develop drugs that could be given in the first few hours following a heart attack to minimise heart muscle death caused by the stress signals. These stress signals actually increase dramatically when the blood supply is restored, so although it is vital to resupply the heart with oxygen and nutrients by reopening the blocked coronary artery, additional treatments to counteract any ‘reperfusion injury’ have been sought for decades.

It’s hoped that this work will be developed into a treatment that could be given as an injection whilst someone is being prepared to receive balloon angioplasty to open up the blocked coronary artery that caused their heart attack.

The treatment is also possibly important in regions and countries where there is limited access to rapid angioplasty, when it could be given whilst the patient is waiting for hospitalisation.

The researchers made their discovery by studying heart samples from people with heart failure and found out that MAP4K4 is activated in these patients. They showed this was also the case in mice after a heart attack, and in human and rodent heart cells and heart tissue subjected to stress signals in the laboratory. They found that if you raise the levels of MAP4K4, heart cells are made more sensitive to stress signals. If you block MAP4K4, the cells are protected, and that is what their designed drug can achieve.

To mimic what might happen in a clinical setting, the mice were given the drug one hour after the blood flow to their hearts was restored. This showed that the drug could reduce heart damage in mice by around 60 per cent.

Notoriously, potential treatments from prior research into prevention of heart muscle death have not proven effective in large clinical trials, but the team believe targeting this new protein, and testing their results in human heart tissue grown from stem cells before moving to trials in heart attack patients, could be the key to success in this area.

These successes have led to a family of potential new drugs being developed for heart attack, with the next steps including rigorous safety testing and a clinical trial, which could start as early as 2021-22.

Facts, background information, dossiers
  • Domainex
  • drug candidates
  • heart attack
More about Domainex
  • News

    Domainex appoints Dr Trevor Perrior as Chief Executive Officer

    Domainex Ltd announced the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly during his tenure, deliv ... more

    Domainex appoints Timo Veromaa as Executive Chairman

    Domainex Ltd announces that Dr Timo Veromaa has been appointed Executive Chairman with immediate effect. His appointment expands and strengthens the existing Board and Executive Management Team; Dr Veromaa will have a pivotal role in leading the organisation through a continuing period of g ... more

    Domainex Secures £1.4m Biomedical Catalyst Award

    Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease (COPD) than either roflumulast or a p38 inhibitor.  It has also successfully won a £1.4m Biomedical Catalyst Award to support further development towar ... more

  • Companies


    Domainex uses unique and proprietary technologies to resolve common bottlenecks facing the pharmaceutical and biotechnology industries in the post-genomic era. Major discovery 'gaps' exist between the vast amount of genomic information that is now available, the accessibility of the corresp ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE